Justin Zelin
Stock Analyst at BTIG
(1.64)
# 3,431
Out of 5,093 analysts
43
Total ratings
26.83%
Success rate
-7.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRSN Mersana Therapeutics | Downgrades: Neutral | n/a | $27.92 | - | 1 | Nov 13, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Buy | $50 | $31.31 | +59.69% | 1 | Nov 10, 2025 | |
| TCRX TScan Therapeutics | Downgrades: Neutral | n/a | $1.00 | - | 2 | Nov 4, 2025 | |
| IPHA Innate Pharma | Reiterates: Buy | $8 | $1.90 | +321.05% | 1 | Oct 29, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $19.98 | +180.28% | 4 | Oct 27, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $35.34 | +75.44% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $0.94 | +754.06% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $37.98 | +229.12% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $1.72 | +306.98% | 3 | Sep 22, 2025 | |
| VSTM Verastem | Reiterates: Buy | $20 | $10.25 | +95.12% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.26 | +165.49% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $20.52 | +104.68% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.97 | - | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $1.25 | +63,900.00% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $38.11 | +138.78% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.52 | +1,807.67% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.35 | +580.85% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $26.12 | +244.56% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $11.64 | +166.32% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $46.77 | -66.86% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $0.93 | +975.27% | 3 | Nov 16, 2022 |
Mersana Therapeutics
Nov 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $27.92
Upside: -
Ascentage Pharma Group International
Nov 10, 2025
Initiates: Buy
Price Target: $50
Current: $31.31
Upside: +59.69%
TScan Therapeutics
Nov 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.00
Upside: -
Innate Pharma
Oct 29, 2025
Reiterates: Buy
Price Target: $8
Current: $1.90
Upside: +321.05%
Syndax Pharmaceuticals
Oct 27, 2025
Reiterates: Buy
Price Target: $56
Current: $19.98
Upside: +180.28%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $35.34
Upside: +75.44%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $0.94
Upside: +754.06%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $37.98
Upside: +229.12%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $1.72
Upside: +306.98%
Verastem
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $10.25
Upside: +95.12%
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.26
Upside: +165.49%
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $20.52
Upside: +104.68%
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.97
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.25
Upside: +63,900.00%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $38.11
Upside: +138.78%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.52
Upside: +1,807.67%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.35
Upside: +580.85%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $26.12
Upside: +244.56%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $11.64
Upside: +166.32%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $46.77
Upside: -66.86%
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $0.93
Upside: +975.27%